Label Changes for:

Mevacor (lovastatin)

February 2014

Changes have been made to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

February 2014

CONTRAINDICATIONS

  • Added…cobicistat-containing products

WARNINGS

Strong inhibitors of CYP3A4:
  • Added…cobicistat-containing products
Table VII
  • Added…cobicistat-containing products

PRECAUTIONS

Information for Patients

Drug Interactions

CYP3A4 Interactions

  • Added…cobicistat-containing products
     
Hide
(web3)